UnknownPhase 2

Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)

South Korea76 participantsStarted 2015-03

Plain-language summary

The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST levels followed by Eglandin administration were assessed.

Who can participate

Age range19 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Primary living donor liver transplantation
✓. Patient received modified right lobe graft
✓. Aged between 19 to 65 years
✓. Informed consent

Exclusion criteria

✕. ABO incompatibility
✕. Dual liver transplant patient from 2 donors
✕. History of liver transplantation or other organ transplantation
✕. Transplantation of other organ(s) at the time of liver transplantation
✕. Use of artificial liver device prior to liver transplantation
✕. UNOS status Ⅰor ⅡA
✕. History of malignant tumor within 5 years
✕. Not included in Milan liver transplant criteria for hepatocellular carcinoma

What they're measuring

Peak AST level within 7 days of Eglandin administration

Timeframe: 7 days

Trial details

NCT IDNCT02350218

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12

View on ClinicalTrials.gov More Evidence of Liver Transplantation trials